* AST, ALT and Alkaline phosphatase \<2.5x upper limit of normal (or \<5x upper limit of normal in the case of liver metastases). Total bilirubin \<1.5x upper limit of normal.
* Estimated creatinine clearance \>50ml/min.
* If female of childbearing potential, pregnancy test is negative and the patient agrees to use an effective method to avoid pregnancy during the study.
You may not be if
HER2 over-expression and/or amplification as determined by immunohistochemistry (3+) or FISH (\>2.0).
* No prior fluoropyrimidine in the metastatic setting. Adjuvant fluoropyrimidine is permitted if \>12 months have elapsed since treatment.
* No restriction for prior hormonal therapy.
* GI malabsorption syndrome which could impair oral drug absorption.
* Concurrent use of warfarin is discouraged as drug interactions may make management of INR more difficult.
* Central nervous system metastases are permitted if previously treated or clinically stable for at least 3 months.
* Pregnant or nursing patients.
* Life expectancy \<3 months.
Clareo Health | Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer
